Boehringer Ingelheim, Ashoka Announce Winners of Health Systems Competition

and global pharmaceutical giant have announced the winners in a global competition to identify business models that provide innovative solutions to critical health systems problems.

Launched in January, the competition is part of a partnership between Boehringer Ingelheim and Ashoka that aims to crowdsource social innovation around the globe and explore unconventional business models. The first- and second-prize winners in the competition will receive $30,000 and $15,000, respectively; a third Idea Prize of $10,000 recognizes an innovative idea that has not yet reached the business-building stage. In addition to their cash prizes, all three winners will receive corporate development consulting services from Boehringer Ingelheim and, along with three additional finalists, will be invited to apply for supplementary grants of up to $30,000.

The winners are Registries for All (first prize) for , which purports to be the world's first participant-controlled, cross-disease registry for health and disease data; (second prize), for Improving Access to Oral Healthcare, a business model that has allowed the only full-time Medicaid provider in Alabama to scale dramatically while lowering the cost of care provision; and (Idea Prize), a nonprofit organization that trains and employs low-income village women outside Bangalore, India, to become community health workers and provide low-cost diabetes diagnostic services in rural communities.

"Once again, our partnership with Boehringer Ingelheim surfaced important innovations that represent leaps forward for patients, caregivers, and health delivery systems," said Diana Wells, president of Ashoka Changemakers, an online community that encourages social entrepreneurs around the globe to share ideas, inspire, and mentor each other. "These winners and finalists are a great example of the kind of gamechanging entrepreneurship that brings us closer to the 'Everyone a Changemaker' reality Ashoka envisions for the future."

"." Boehringer Ingelheim Press Release 07/10/2013.